Abstract |
Treatment with imatinib is very effective in Bcr-Abl positive leukemia. However, development of resistance to this drug is a common phenomenon in late stage disease. The Bcr-Abl protein localizes to the cytoplasm in transformed cells but can enter the nucleus upon treatment with imatinib. Using leptomycin B, a nuclear export blocker, it has been shown that reactivated nuclear Bcr-Abl kinase activity can induce cell death, thus presenting an interesting potential treatment option for imatinib resistant disease. Here we show that the combination of imatinib and leptomycin B effectively induces cell death in imatinib-resistant Ba/F3 cells which display Bcr-Abl amplification or signs of clonal evolution. However, no such synergism is observed in imatinib-resistant Ba/F3 cells carrying the T315I mutation of Bcr-Abl or those which have lost Bcr-Abl expression. Thus, a partial inhibition of Bcr-Abl by imatinib is required for this approach in agreement with the proposed mode of action.
|
Authors | Rama Krishna Kancha, Nikolas von Bubnoff, Cornelius Miething, Christian Peschel, Katharina S Götze, Justus Duyster |
Journal | Haematologica
(Haematologica)
Vol. 93
Issue 11
Pg. 1718-22
(Nov 2008)
ISSN: 1592-8721 [Electronic] Italy |
PMID | 18728023
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Antineoplastic Agents
- Benzamides
- Fatty Acids, Unsaturated
- Piperazines
- Pyrimidines
- Imatinib Mesylate
- Protein-Tyrosine Kinases
- Fusion Proteins, bcr-abl
- leptomycin B
|
Topics |
- Antineoplastic Agents
(pharmacology)
- Benzamides
- Cell Line, Tumor
- Cell Survival
(drug effects)
- Chromosomes, Human, Pair 22
- Chromosomes, Human, Pair 9
- Colony-Forming Units Assay
- Drug Resistance
(physiology)
- Fatty Acids, Unsaturated
(pharmacology)
- Fusion Proteins, bcr-abl
- Gene Amplification
- Genes, abl
(genetics)
- Humans
- Imatinib Mesylate
- Leukemia, Myelogenous, Chronic, BCR-ABL Positive
(genetics)
- Mutation
- Philadelphia Chromosome
- Piperazines
(pharmacology)
- Precursor Cell Lymphoblastic Leukemia-Lymphoma
(genetics)
- Protein-Tyrosine Kinases
(genetics)
- Pyrimidines
(pharmacology)
- Translocation, Genetic
|